

Date: April 20, 2026

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

Scrip Code: 544742

**National Stock Exchange of India Limited**

Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400 051  
Trading Symbol: SAIPARENT

ISIN: INE0H9F01037

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on today i.e. Monday, April 20, 2026**

---

In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of Sai Parenteral's Limited ("the Company") at its meeting held today i.e. Monday, April 20, 2026, *inter-alia* considered and approved the following:

**1. Investment / Loan in Wholly Owned Subsidiary i.e. Sai Singapore Pte. Ltd. for downstream Investment in Noumed Pharmaceuticals PTY Limited, Australia**

The Board approved provision of financial assistance by way of unsecured loan not exceeding AUD 1.75 million or SGD 1.610 million which is equivalent to INR 11,91,40,000/- to Sai Singapore Pte. Ltd. (wholly owned subsidiary of the Company) for downstream funding to Noumed Pharmaceuticals Pty Limited, Australia (Step-down Subsidiary of the Company).

The Board meeting commenced at 12:00 Noon and concluded at 02:40 Noon.

The above information will also be made available on Company's website i.e. [www.saiparenterals.com](http://www.saiparenterals.com)

Kindly take the above on record.

Thanking you,

Yours faithfully,  
**For Sai Parenteral's Limited**

**Anil Kumar Karusala**  
**Chairman and Managing Director**  
**DIN: 01866646**